Brief Title: A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Part 1 Arm A: Average concentration of ipilimumab (Cavg21d)

Primary Outcome 1 - Timeframe: Day 21

Primary Outcome 2 - Measure: Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d)

Primary Outcome 2 - Timeframe: Day 21

Primary Outcome 3 - Measure: Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax)

Primary Outcome 3 - Timeframe: Up to 21 days

Primary Outcome 4 - Measure: Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d)

Primary Outcome 4 - Timeframe: Day 21

Primary Outcome 5 - Measure: Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)

Primary Outcome 5 - Timeframe: Up to 21 days

Primary Outcome 6 - Measure: Part 2 Arm A: Average concentration in ipilimumab (Cavg42d)

Primary Outcome 6 - Timeframe: Day 42

Primary Outcome 7 - Measure: Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d)

Primary Outcome 7 - Timeframe: Day 42

Primary Outcome 8 - Measure: Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax)

Primary Outcome 8 - Timeframe: Up to 42 days

Primary Outcome 9 - Measure: Part 2 Arm A: Observed concentration in ipilimumab (C42d)

Primary Outcome 9 - Timeframe: Day 42

Primary Outcome 10 - Measure: Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)

Primary Outcome 10 - Timeframe: Up to 42 days

Primary Outcome 11 - Measure: Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d)

Primary Outcome 11 - Timeframe: Day 21

Primary Outcome 12 - Measure: Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d)

Primary Outcome 12 - Timeframe: Day 21

Primary Outcome 13 - Measure: Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax)

Primary Outcome 13 - Timeframe: Up to 21 days

Primary Outcome 14 - Measure: Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d)

Primary Outcome 14 - Timeframe: Day 21

Primary Outcome 15 - Measure: Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax)

Primary Outcome 15 - Timeframe: Up to 21 days

CONDITION

• Tumor

ELIGIBILITY

Gender: All

Minimum Age: N/A

Maximum Age: 18 Years

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Bristol-Myers Squibb

Role: Study Director

Affiliation: Bristol-Myers Squibb

Overall Contact

Name: Bristol-Myers Squibb

Phone: please email:

Email: Clinical.Trials@bms.com

LOCATION